Carl Zeiss Meditec AG expects revenue for fiscal year 2019/20 of approx. EUR 1.3 billion

Jena, Germany | July 15, 2020  | Carl Zeiss Meditec AG

In view of the continuing Covid-19 pandemic and its impact on relevant markets, Carl Zeiss Meditec AG (ISIN: DE0005313704) expects to see a further impact on business development in the remainder of fiscal year 2019/20 compared to previous year.

Assuming a recovery in markets and, in particular, that no significant additional measures to contain the Covid-19 pandemic will impact development, management anticipates revenue of around EUR 1.3 billion for fiscal year 2019/20 (previous year EUR 1.459 billion).

In the first nine months of fiscal year 2019/20, Carl Zeiss Meditec has achieved revenue of EUR 967.9 million (previous year EUR 1,027.6 million). This corresponds to a decline of 5.8% vs. the previous year. After adjustment for currency effects , the decline amounted to 6.9%.

Earnings before interest and taxes (EBIT) amounted to EUR 111.9 million after the first nine months of 2019/20 (previous year: EUR 184.2 million). Earnings per share (EPS) were EUR 0.77 (previous year: EUR 1.22).

The quarterly statement of the first nine months of fiscal year 2019/20 will be published on August 5, 2020.

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of €1,459.3m in fiscal year 2018/19 (as of 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Share
Downloads
Further Articles

Tender of Annual Audit Services

For Carl Zeiss Meditec AG

May 12, 2020

Insider Information

Revenue in second quarter of 2019/20 stagnating - Further impact on business development expected for second half 2019/20 - Currently no outlook for 2019/20 possible

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approx. EUR 715 million (previous year EUR 667.2 m...

Apr 2, 2020

Insider Information

Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19

Oct 23, 2019